Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in a $10 billion cash deal, expanding Vertex’s commercial pillars beyond cystic fibrosis and deep into endocrine rare diseases. The acquisition adds Palsonify (paltusotine) and a late-stage endocrine asset, with Vertex describing the move as a strategic “fifth pillar.” Under the terms, Vertex will pay $85 per share to Crinetics shareholders, valuing Crinetics at roughly $10 billion in equity terms and positioning the assets for commercialization in specialty endocrinology. Vertex also expects peak combined sales potential of more than $5 billion from Palsonify and atumelnant, according to the deal overview. The transaction is set for completion in the third quarter of 2026, after unanimous board approvals. Vertex will fund the buyout with cash and committed bridge financing, aiming to leverage Vertex’s commercial infrastructure to scale Palsonify uptake and develop atumelnant in congenital adrenal hyperplasia (CAH).